Novel paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy
申请人:PHARMACHEMIE B.V.
公开号:EP0781778A1
公开(公告)日:1997-07-02
The invention relates to novel, water-soluble paclitaxel prodrugs wherein paclitaxel is, through its 2'-hydroxyl functionality, connected to a cleavable spacer group, which is in turn attached to a preferably enzymatically cleavable sugar group. Such prodrugs are relatively non-toxic and can be used in cancer treatment. They can be selectively activated at the tumor site by the action of endogeneous enzymes or targeted enzymes, or via a non-enzymatic process. The enzyme is preferably β-glucuronidase, β-glucosidase or β-galactosidase. The invention also relates to a process for preparing a pharmaceutical composition containing a paclitaxel prodrug as defined herein, which comprises said prodrug with a pharmaceutically acceptable carrier to provide a solid or liquid formulation for administration.
本发明涉及新型水溶性紫杉醇原药,其中紫杉醇通过其 2'-羟基官能团与可裂解的间隔基团相连,而间隔基团又与优选的可酶裂解的糖基相连。这种原药相对无毒,可用于癌症治疗。它们可以通过内源酶或靶向酶的作用,或通过非酶过程,在肿瘤部位被选择性激活。酶最好是β-葡萄糖醛酸酶、β-葡萄糖苷酶或β-半乳糖苷酶。本发明还涉及一种制备含有本文定义的紫杉醇原药的药物组合物的工艺,该组合物由所述原药与药学上可接受的载体组成,以提供固体或液体给药制剂。